Meanwhile, the humanized anti-CD26/DPP4 mAb YS110 (NCT03177668) has already been tested in humans for its safety and efficacy for the treatment of aggressive malignant mesothelioma, a disease with otherwise still very limited treatment options [102,103]. Here, DPP4 is linked to malignant mesothelioma.